Pediatric Schizophrenia Efficacy and Safety Study
NCT01911429
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
327
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
Lurasidone 40 mg
DRUG:
Lurasidone 80 mg
DRUG:
Placebo 40 or 80 mg
Sponsor
Sumitomo Pharma America, Inc.